期刊档案 · Medicine-Infectious Diseases

JACAntimicrobial Resistance

ISSN 2632-1823 · Oxford University Press · United Kingdom

JACAntimicrobial Resistance 中科院 医学 4区(2025 年升级版),影响因子 5.3(官网公布),完全开放获取,收取 APC,金额未公布,近 24 个月 67 篇文章投稿到接收中位 97 天,2025 年发文 462 篇,Scopus 收录。

影响因子5.3期刊官网公布的 2025 年度值
中科院分区医学 4区2025 年升级版大类 · 2026 新锐版 医学 3区
审稿周期97 天投稿到接收中位数 · 近 24 个月 67 篇文章 · PubMed
版面费收取 APC,金额未公布完全开放获取
录用比例—暂无反馈
年发文量462 篇2025 年 · OpenAlex 统计

研究范围

研究范围与定位

JACAntimicrobial Resistance 由 Oxford University Press 出版,属中科院医学大类(2025 升级版4区)。按 OpenAlex 近年发文统计,该刊主要发表 Antibiotic Use and Resistance、Antibiotic Resistance in Bacteria、Antibiotics Pharmacokinetics and Efficacy 等主题的论文,这 3 个主题约占 49%。(根据 OpenAlex 主题统计与中科院分区数据生成)

JAC-Antimicrobial Resistance (JAC-AMR) is a fully open access Society journal from the British Society for Antimicrobial Chemotherapy (BSAC). As one of the most important threats to global health, antimicrobial resistance requires an innovative, interdisciplinary response. The mission of JAC-AMR is to disseminate cutting-edge research, and provide education regarding the origins, spread, characteristics, diagnosis, treatment, and prevention of multi-drug resistant organisms that result in difficult-to treat infections around the world. We publish original research articles, reviews, clinically oriented opinions and viewpoints, debates, brief reports, and reviews of educational resources. JAC-AMR focuses on advancing the science and knowledge of antimicrobial resistance, stewardship and use relating to antibacterial, antifungal, antiviral and antiprotozoal agents. The Journal recognizes the importance of the “One Health” framework to understand AMR, and encourages AMR investigations that cover the spectrum of environment, animal and human health. JAC-AMR is dedicated to the dissemination of research on antimicrobial stewardship practices, and encourages the use of rigorous non-quantitative methodology where appropriate. Publishing with JAC-Antimicrobial Resistance As a JAC-AMR author, you support the British Society for Antimicrobial Chemotherapy (BSAC) and join a rich community dedicated to saving lives by fighting infection. BSAC members are eligible for a reduced APC, and APCs are waived for authors in developing countries and regions. JAC-AMR authors, reviewers, and editors are part of a forward-thinking, innovative community with a focus on scientific excellence and interdisciplinary approaches to advancing our field. Discover the latest journal metrics (including readership, category rankings, and article processing times) in the below table. A global audience for your work JAC-AMR connects powerful ideas with the widest audience to give your research the greatest possible impact. Strong annual readership from around the globe An impressive CiteScore (Scopus) and a strong Impact Factor (Clarivate) Indexed in PubMed, Web of Science, and Scopus, making content easily discoverable. View our full list of indexing services at the bottom of this page. 96% of JAC articles mentioned online*, via news outlets, policy documents, clinical guidelines, and social media. Research has appeared in news outlets and policy documents from sources including The Independe

摘自期刊官网 Aims & Scope

研究方向(LetPub):Medicine-Infectious Diseases

主编 David van Duin.出版商官网

编委会国家分布:中国大陆 2 位(约 2%);主要国家 美国 35、英国 23、南非 8、印度 7、澳大利亚 5(共 120 位编委标注了国家) 编委会 ↗出版商官网 ·

主要研究主题 OpenAlex 近年发文统计,占比为近似值

  1. Antibiotic Use and ResistanceImmunology and Microbiology24.3%
  2. Antibiotic Resistance in BacteriaBiochemistry, Genetics and Molecular Biology15.3%
  3. Antibiotics Pharmacokinetics and EfficacyMedicine9.4%
  4. Bacterial Identification and Susceptibility TestingBiochemistry, Genetics and Molecular Biology7.1%
  5. Urinary Tract Infections ManagementMedicine6.2%
  6. Nosocomial Infections in ICUMedicine4.7%
  7. Antimicrobial Resistance in StaphylococcusMedicine4.5%
  8. Pharmaceutical and Antibiotic Environmental ImpactsEnvironmental Science3.8%

分区与收录

学科分区与数据库收录

中科院期刊分区表

期刊分区表( 2025年3月升级版)医学 4 区
类别学科分区
大类医学4 区
小类微生物学MICROBIOLOGY3 区
小类药学PHARMACOLOGY & PHARMACY3 区
小类传染病学INFECTIOUS DISEASES4 区

Top 期刊:否综述期刊:否

《新锐期刊分区表》( 2026年3月发布)医学 3 区
类别学科分区
大类医学3 区
小类传染病学INFECTIOUS DISEASES3 区
小类微生物学MICROBIOLOGY3 区
小类药学PHARMACOLOGY & PHARMACY3 区

Top 期刊:否综述期刊:未标注

期刊分区表( 2023年12月旧的升级版)未收录

该期刊未被此版本分区表收录。

数据库收录

ScopusDOAJLetPub

国际期刊预警名单:各版本均未列入LetPub

期刊官网自述收录

ESCIWeb of SciencePMC出版商官网

期刊官网列出的收录清单,未与各数据库逐一核对;Web of Science 各子库以上方记录为准。

不同版本、大类与小类分别展示,不将不同评价口径合并为一个分区值;投稿与考核前请确认所在机构采用的版本。

指标

影响力指标与发文规模

影响力指标

影响因子(出版商公布) 2025
5.3出版商官网 ·
五年影响因子(出版商公布) 2025
4.4出版商官网 ·
CiteScore 2026-06
5.3LetPub ·
CiteScore(出版商公布) 2025
5.3出版商官网 ·
SJR 2026-06
1.06LetPub ·
SNIP 2026-06
1.18LetPub ·
h-index
48OpenAlex ·
i10-index
374OpenAlex ·
两年平均被引
2.51OpenAlex ·
Gold OA 文章占比
0%LetPub ·

发文规模

年下载量(出版商公布) 2025
500,522出版商官网 ·

逐年发文量 OpenAlex 统计 · 累计 2,022 篇 · 当年数据不完整

年份发文量其中 OA被引
202634934963
2025462462960
20242902901,738
20232712711,867
20222312312,684
20212082083,834

不同来源的统计口径与观测时间不同,页面保留各来源原值;“出版商公布”为期刊官网自述数据。

审稿与录用

审稿周期与录用情况

文章统计的审稿周期 PubMed 登记的稿件日期 · 至

97 天投稿到接收中位数 · P25–P75 72 天 – 130 天

接收到上线
中位数 21 天(67 篇)
投稿到上线
中位数 115 天
样本
67 篇有投稿与接收日期的文章(窗口内共 536 篇),最近一篇接收于

只统计最终被录用并发表的文章,不含被拒稿件的处理时间,因此通常长于出版商公布的"首次决定时间"。

其他来源

平均审稿速度(社区反馈)
16 WeeksLetPub ·
投稿到首次决定
12 天出版商官网 ·
投稿到首次决定 2025
24 天出版商官网 ·
投稿到最终决定 2025
43 天出版商官网 ·
接收到发表
23.5 天出版商官网 ·
投稿到发表(期刊自报)
约 16 周DOAJ ·
评审方式
同行评审(未说明方式)DOAJ

社区反馈来自投稿者样本,置信度 0.5,不代表期刊承诺;“出版商公布”的时间节点定义以官网为准。

费用与开放获取

版面费与开放获取政策

完全开放获取DOAJ

所有文章开放获取,通常向作者收取文章处理费(APC)。

来源文章处理费费用减免许可证观测时间
DOAJGBP 1,883有CC BY、CC BY-NC、CC BY-NC-ND
OpenAlexGBP 1,978——
LetPubGBP 1,883有—
出版商官网有,金额未公布——

其他费用与减免(作者指南)

版面费
USD 3,625

费用以期刊官网为准;不同来源的观测时间可能不同,页面保留各来源原值,不做平均。

投稿要求

文章类型与投稿政策(官网)

投稿准备要点4 项,摘自作者指南
摘要
≤ 250 词
正文篇幅
≤ 3,500 词
投稿信(Cover letter)
必须提供
不接收
claims of priority in article titles
出版商官网 · 模型提取,逐项与原文核对
接收的文章类型9 种,含篇幅限制
  1. brief reportAll documents should be double spaced, and the margins should not be excessively wide. A clear, legible single font (which is readily available internationally)…正文 ≤ 1,500 词 · 参考文献 ≤ 20
  2. brief reportsBrief reports These should have the same format as Original未说明篇幅
  3. correspondenceLetters on topics of concern or interest in the field of antimicrobial chemotherapy, particularly arising from papers or letters already published in the Journa…正文 ≤ 800 词 · 参考文献 ≤ 10
  4. original articleAll documents should be double spaced, and the margins should not be excessively wide. A clear, legible single font (which is readily available internationally)…正文 ≤ 3,500 词
  5. original researchAll documents should be double spaced, and the margins should not be excessively wide. A clear, legible single font (which is readily available internationally)…未说明篇幅
  6. review articleThere is no length limit for this format. These generally aim to give an overview of a field suitable for a wide audience, and they should include a synopsis (2…正文 ≤ 250 词
  7. review articlesThere is no length limit for this format. These generally aim to give an overview of a field suitable for a wide audience, and they should include a synopsis (2…未说明篇幅
  8. viewpointAll documents should be double spaced, and the margins should not be excessively wide. A clear, legible single font (which is readily available internationally)…正文 ≤ 1,000 词
  9. viewpoint and review articlesViewpoint and review articles: will usually be solicited by one of the Editors unsolicited viewpoint or review articles will be considered only after prior disc…未说明篇幅
出版商官网
官网政策摘录作者资格、利益冲突、数据可用性、出版伦理、许可与版权、开放获取、同行评审、预印本、自存档
作者资格 Authorship

作者署名应仅限于对所描述工作的设计和执行做出重大贡献的人。对于临床试验/随机对照试验,必须在透明声明部分的利益冲突信息之后明确说明每位作者的贡献。其他类型文章的作者可以自行选择是否说明每位作者的贡献。JAC 建议作者在投稿前查阅 ICMJE 的作者资格标准。 模型中文摘要

The authorship of the paper should be confined to those who have made a significant contribution to the design and execution of the work described. In the case of clinical trials/randomized control trials it is compulsory for the contribution of each author to be clearly stated in the Transparency declarations section, after the information on conflicts of interest. Authors of other types of artic…

原文 ↗出版商官网 ·
利益冲突 Conflicts of interest

利益冲突可能影响作者、审稿人和编辑(包括高级编辑和主编)。JAC-AMR 建立了以下处理利益冲突的制度:作者。每位投稿都必须包含透明声明部分。审稿人。在被邀请时以及同意担任审稿人时,审稿人都会被提醒考虑自己是否存在潜在的利益冲突,并被要求与该文章的编辑讨论任何可察觉的潜在冲突。 模型中文摘要

Conflicts of interest have the potential to affect authors, referees and Editors (including Senior Editors and the Editor-in-Chief). JAC-AMR has the following systems in place to deal with conflicts of interest: Authors. Authors are required to include a Transparency declarations section in every submission to the Journal (for details see below). Referees. When invited to act, and again when they …

原文 ↗出版商官网 ·
数据可用性 Availability of Data and Materials

在伦理允许的情况下,JAC-AMR 强烈鼓励作者向读者提供论文结论所依赖的所有数据和软件代码。建议尽可能在主稿或附加支持文件中呈现数据,或存入公共存储库。 模型中文摘要

Where ethically feasible, JAC-AMR strongly encourages authors to make all data and software code on which the conclusions of the paper rely available to readers. We suggest that data be presented in the main manuscript or additional supporting files, or deposited in a public repository whenever possible. For information on general repositories for all data types, and a list of recommended reposito…

原文 ↗出版商官网 ·
出版伦理 Misconduct

期刊将积极追究针对作者、编辑或审稿人的不当行为指控,并拥有多种制裁手段,包括将指控告知雇主并要求其开展内部调查。指控不应轻率提出,也不应在缺乏获得支持证据可能性的情况下提出。如果找不到支持证据,期刊可能认为指控属于恶意,并可能对指控者实施制裁。任何不当行为指控都应提交给主编。 模型中文摘要

We will energetically pursue accusations of misconduct directed at authors, Editors or referees and have a number of sanctions at our disposal including the option to inform employers about accusations and ask them to mount their own internal investigations. Accusations should not be made lightly or in the absence of the likelihood of supporting evidence being obtainable. The Journal may take the …

原文 ↗出版商官网 ·
许可与版权 Copyright

稿件被接收后,作者将受邀填写在线版权许可发表表。由 Wellcome Trust 或 RCUK 资助的论文可以选择符合其开放获取政策的知识共享署名许可(CC-BY)。提交文章即确认您是通讯/投稿作者,牛津大学出版社(OUP)可保留您的电子邮件地址以便就文章与您沟通,且您同意立即通知 OUP 任何变更。 模型中文摘要

Upon receipt of accepted manuscripts at Oxford Journals authors will be invited to complete an online copyright licence to publish form. Papers funded by the Wellcome Trust or RCUK will be given the option to select the Creative Commons Attribution licence (CC-BY) in compliance with their open access policies. Please note that by submitting an article for publication you confirm that you are the c…

原文 ↗出版商官网 ·
开放获取 Third-party content in Open Access papers

如果文章包含您没有开放获取再使用许可的材料,请在该材料旁明确提供以下署名行:内容标题、作者、原出版物、原发表年份、经 [权利持有人] 许可。此图像/内容不受本出版物知识共享许可条款的约束。如需再使用许可,请联系权利持有人。 模型中文摘要

If your article contains material for which you do not have Open Access re-use permissions, please state this clearly by supplying the following credit line alongside the material: Title of content Author, Original publication, year of original publication, by permission of [rights holder] This image/content is not covered by the terms of the Creative Commons licence of this publication. For permi…

原文 ↗出版商官网 ·
同行评审 Peer review

JAC-AMR 实行单盲同行评审。编辑部工作人员对投稿进行初步检查以确认所有必要要素齐全后,稿件将转交主编,主编再将稿件指派给合适的高级编辑,高级编辑负责选择一位编辑处理稿件。主编、高级编辑或编辑可以不经进一步同行评审立即拒稿。负责的编辑负责选择审稿人并获取审稿报告。 模型中文摘要

JAC-AMR follows single-blind peer review. After preliminary examination of the submission by Editorial Office staff to check that all the necessary elements are present, the manuscript is passed to the Editor-in-Chief. The Editor-in-Chief then assigns the manuscript to an appropriate Senior Editor. The Senior Editor is then responsible for selecting an Editor to handle the manuscript. Manuscripts …

原文 ↗出版商官网 ·
预印本 Preprint Policy

作者保留通过多种渠道提供作者原始版本(预印本)的权利,这不影响向期刊投稿。如被接收,作者必须更新任何预印本的状态,包括已发表论文的 DOI。 模型中文摘要

Authors retain the right to make an Author’s Original Version (preprint) available through various channels, and this does not prevent submission to the journal. For further information see our Online Licensing, Copyright and Permissions policies. If accepted, the authors are required to update the status of any preprint, including your published paper’s DOI, as described on our Author Self-Archiv…

原文 ↗出版商官网 ·
自存档

有关 JAC-AMR 的自存档政策,请访问其作者自存档政策页面。 模型中文摘要

For information about JAC-AMR's policy, please visit our Author Self-Archiving Policy Page.

原文 ↗出版商官网 ·

摘录来自期刊官网页面,仅保留原文片段;“模型摘要”由 Workers AI 生成并经原文校验,以官网为准。

基本信息

出版信息与官方入口

出版商
Oxford University Press
出版国家或地区
United Kingdom
出版语言
English
ISSN
2632-1823
官网最新一期
Volume 8, Issue 5(2026 年 10 月)
官方链接

常见问题

关于 JACAntimicrobial Resistance 的常见问题

JACAntimicrobial Resistance 是中科院几区期刊?

2025 年升级版分区表中,JACAntimicrobial Resistance 为医学 4区,小类 微生物学 / 药学 / 传染病学 3 区。2026 年新锐版分区表中为医学 3区。不同版本与大小类分区不能混用。

JACAntimicrobial Resistance 的影响因子是多少?

期刊官网公布的影响因子为 5.3(2025 年度),属期刊自述数据,LetPub 暂无该刊的影响因子记录,CiteScore 为 5.3,h-index 为 48。

JACAntimicrobial Resistance 的审稿周期多长?

按 2024年10月至2026年10月(近 24 个月)67 篇已发表文章登记的日期,投稿到接收的中位数为 97 天(四分位 72–130 天);投稿社区反馈的平均审稿速度为约 16 周。文章统计只含被录用的稿件,出版商数据口径以官网为准,社区反馈来自投稿者样本,均不代表期刊承诺。

JACAntimicrobial Resistance 的投稿格式要求是什么?

据期刊作者指南:摘要:≤ 250 词;正文篇幅:≤ 3,500 词;投稿信:必须提供。以上由模型从作者指南提取并逐项与原文核对,投稿前请以官网最新版本为准。

JACAntimicrobial Resistance 的编委会里有中国学者吗?

期刊官网编委会页面上标注了国家的 120 位编委中,中国大陆 2 位(约 2%);人数最多的国家是 美国(35 位)、英国(23 位)、南非(8 位)。统计按编委会页面列出的机构国家计,仅供参考。

JACAntimicrobial Resistance 被哪些数据库收录?

据 LetPub 与 DOAJ 记录,JACAntimicrobial Resistance 被 Scopus、DOAJ 收录。期刊官网自述还被 ESCI、Web of Science、PMC 收录,该清单未与各数据库逐一核对。

JACAntimicrobial Resistance 是开放获取期刊吗?版面费多少?

JACAntimicrobial Resistance 为完全开放获取。收取 APC,金额未公布。

来源与更新

本页事实来自 LetPub、出版商官网、OpenAlex、DOAJ;每个数字旁标注来源与观测日期,冲突数据保留各来源原值。LetPub 原始详情页:查看 ↗(2026-08-25 归档)。最近更新:。